Fingolimod is effective in IFN-β non-responder patients with high Sema4A.
Relapses (A) and EDSS (B) of all the patients with high Sema4A in Osaka University Hospital who changed from IFN-β to fingolimod treatment are shown. (The orange and blue lines represent duration of treatment with fingolimod and IFN-β, respectively.) During IFN-β treatment, the patients had many relapses and disease progressed. However, fingolimod tended to be effective in reducing the relapse rate (1.36 ± 0.80 (IFN-β) to 0.27 ± 0.25 (FTY), p = 0.054; Mann-Whitney U test) and in preventing further increase in EDSS in all patients (0.45 ± 0.37 (annual EDSS change, IFN-β) to 0.0 ± 0.0 (annual EDSS change, FTY), p = 0.046; Mann-Whitney U test). The Sema4A levels (U/ml) of each patient are as follows: Pt.1; 24098, Pt.2; 3500, Pt.3; 3915, Pt.4; 6484, Pt.5; 21186, indicated within the parenthesis.